OncoMatch/Clinical Trials/NCT06878625
A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer
Is NCT06878625 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Sacituzumab Govitecan combined with Toripalimab and Sacituzumab govitecan combined with anti-angiogenesis for evaluating the efficacy of trop-2 adc combination therapy in advanced triple-negative breast cancer.
Treatment: Sacituzumab Govitecan combined with Toripalimab · Sacituzumab govitecan combined with anti-angiogenesis — Research purposes: the research design in the late more than 2 lines TNBC prospective, multicenter, cohort study, respectively to observe Trop2 - ADC joint PD - 1 single or combined anti-angiogenesis drugs (macromolecular single bevacizumab or small molecules TKI resistance, for, as the default layered) the efficacy and safety. Indications: Trop2 - ADC joint PD - 1 single or combined anti-angiogenesis drugs (macromolecular single bevacizumab or small molecules TKI resistance, for, as the default layered) treat above 2 late three negative breast cancer (TNBC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Required: ESR1 expression < 10% (< 10%)
immunohistochemical detection of ER < 10%
Required: PR (PGR) expression < 10% (< 10%)
immunohistochemical detection of PR < 10%
Required: HER2 (ERBB2) 0-1+ by IHC or 2+ with negative FISH or CISH (0-1+ by IHC or 2+ with negative FISH or CISH)
HER2 0-1+ or HER2 2+ with negative FISH or CISH results
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemotherapy — advanced treatment phase
patients received at least one but no more than two lines of chemotherapy in the advanced treatment phase
Cannot have received: immunotherapy
No prior use of immunotherapy
Cannot have received: anti-angiogenic drug
No prior use of anti-angiogenic drugs
Lab requirements
Blood counts
hemoglobin ≥90 g/l without transfusion within 14 days; absolute neutrophil count (anc) ≥1.5×10^9/l; platelets ≥75×10^9/l
Kidney function
serum creatinine ≤1×uln
Liver function
total bilirubin ≤1.5×uln; ast and alt ≤3×uln (≤5×uln if liver metastasis present)
Cardiac function
left ventricular ejection fraction (lvef) ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify